Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Market Cap: US$390.7m

Sana Biotechnology Management

Management criteria checks 3/4

Sana Biotechnology's CEO is Steve Harr, appointed in Sep 2018, has a tenure of 6.25 years. total yearly compensation is $2.67M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth $15.50M. The average tenure of the management team and the board of directors is 0.9 years and 5.4 years respectively.

Key information

Steve Harr

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage24.7%
CEO tenure6.3yrs
CEO ownership4.0%
Management average tenureless than a year
Board average tenure5.4yrs

Recent management updates

Recent updates

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Dec 04

Sana Biotechnology: The Story Becomes Murkier

Nov 19

We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Nov 01
We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

CEO Compensation Analysis

How has Steve Harr's remuneration changed compared to Sana Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$306m

Jun 30 2024n/an/a

-US$245m

Mar 31 2024n/an/a

-US$309m

Dec 31 2023US$3mUS$659k

-US$283m

Sep 30 2023n/an/a

-US$276m

Jun 30 2023n/an/a

-US$362m

Mar 31 2023n/an/a

-US$320m

Dec 31 2022US$4mUS$645k

-US$269m

Sep 30 2022n/an/a

-US$300m

Jun 30 2022n/an/a

-US$298m

Mar 31 2022n/an/a

-US$207m

Dec 31 2021US$1mUS$611k

-US$356m

Sep 30 2021n/an/a

-US$358m

Jun 30 2021n/an/a

-US$327m

Mar 31 2021n/an/a

-US$433m

Dec 31 2020US$7mUS$535k

-US$285m

Compensation vs Market: Steve's total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Harr (54 yo)

6.3yrs

Tenure

US$2,671,662

Compensation

Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Harr
President6.3yrsUS$2.67m3.97%
$ 15.5m
Susan Wyrick
Acting CFOless than a yearno data0.066%
$ 258.1k
Snehal Patel
Senior VP & Chief Technical Officerless than a yearno datano data
Dhavalkumar Patel
Executive VP & Chief Scientific Officerless than a yearno datano data
Bernard Cassidy
Executive VP2.3yrsUS$4.26m0.042%
$ 162.4k
Sonja Schrepfer
Senior VP & Head of Hypoimmune Platform5.8yrsno datano data
Gary Meininger
Chief Medical Officer1.7yrsno datano data
Yuko Soneoka
Head of Intellectual Propertyless than a yearno datano data
John Gerecitano
Head of Oncology Research & Developmentless than a yearno datano data

0.9yrs

Average Tenure

54yo

Average Age

Experienced Management: SANA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Harr
President6.2yrsUS$2.67m3.97%
$ 15.5m
Robert Taylor Nelsen
Independent Director6.2yrsUS$294.80k0.0062%
$ 24.2k
Mary Wilderotter
Independent Director4.6yrsUS$314.80k0.0032%
$ 12.4k
Douglas Cole
Independent Director4.7yrsUS$302.30k0.091%
$ 354.1k
Yuhmin Yang
Independent Director6.2yrsUS$299.80k0.067%
$ 261.2k
Michelle Seitz
Independent Director4.1yrsUS$314.80k0%
$ 0
Richard Mulligan
Vice Chairman6.1yrsno data1.21%
$ 4.7m
Hans Edgar Bishop
Independent Chairman of the Board6.2yrsUS$354.80k2.59%
$ 10.1m
Joshua Bilenker
Independent Director4yrsUS$299.80k0.0090%
$ 35.0k
Alise Reicin
Independent Director4yrsUS$302.30k0%
$ 0

5.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: SANA's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sana Biotechnology, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Alec StranahanBofA Global Research
Samantha Lynn SemenkowCitigroup Inc